Premise Data Wins Prestigious Urban Innovation Challenge from Gavi, the Vaccine Alliance

SAN FRANCISCO, Aug. 8, 2019 /PRNewswire/ — Data and analytics platform Premise Data announced today it was named an INFUSE Pacesetter by Gavi, the Vaccine Alliance—a privileged partner designation that includes an infusion of capital and expertise to help Premise scale its technology to improve immunization coverage across the developing world. 

Premise will increase vaccine rates by optimizing immunization deliveries, observing sessions for compliance, monitoring inventory and clinic infrastructure, and surveying attitudes toward immunization. The Bill & Melinda Gates Foundation chose Premise to pilot a vaccine monitoring program in Nigeria and the Democratic Republic of Congo. Gavi then selected Premise for its ability to scale rapidly to new countries.

Only 80 percent of children globally are immunized. The 20 percent of children who go un-immunized, colloquially referred to as “the fifth child,” mostly reside in dense urban areas, very remote areas, or in conflict zones.

“We are honored to have the life-saving work we do recognized,” said Premise CEO Maury Blackman, “and we’re thrilled to see how our technology, coupled with new thinking, is helping immunize ‘the fifth child,'” he said. There were more than 100 applicants for the program and Premise was one of three winners.

Gavi’s mission is to ensure that every child around the world is immunized with basic life-saving vaccines, no matter where they live. Gavi launched INFUSE–Innovation for Uptake, Scale and Equity in Immunisation–at the 2016 World Economic Forum in Davos to help improve vaccine delivery systems by connecting high-impact innovations with the countries that need them the most.

“Winning INFUSE helps Premise and our partner governments successfully monitor the performance of their immunization systems in real-time—a massive step forward in the process of digital transformation,” added Chris Watson, Premise’s business development manager for international development.

Premise works on a range of industry and development projects with private and public partners. For more information, visit Premise.com.

About Premise:
Premise helps customers unlock a world of ground-level data. By combining the power of a global network of on-the-ground Contributors with industry-leading data science and machine learning, Premise empowers decision makers with the high-quality, trustworthy data they need. Premise is headquartered in San Francisco, CA, with offices in Washington, D.C., Seattle, WA and Portland, OR. Find more information at www.premise.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/premise-data-wins-prestigious-urban-innovation-challenge-from-gavi-the-vaccine-alliance-300899036.html

SOURCE Premise Data

Staff

Recent Posts

Massimo Group Signs Letter of Intent to Acquire 100% of AI technology company FST in Drive to Accelerate Its AI-Powered Mobility and Health Technology Strategy

GARLAND, Texas, Feb. 3, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO) ("Massimo" or the "Company"),…

33 minutes ago

Baysient Launches iDose® GEN7.0, Expanding Precision Dosing Platform to 16 Inflammatory Disease Indications

Next-Generation Decision Support Software Introduces Predictive Clinical Tools for Gastroenterology, Rheumatology, Dermatology, and PulmonologyFORT MYERS,…

33 minutes ago

From the Founders of Fitbit: Introducing Luffu, Your Guardian for Family Health & Safety

After making personal health accessible to millions with Fitbit, James Park and Eric Friedman announce…

33 minutes ago

Embla Medical hf: Interim Report Q4 and Full Year 2025

COPENHAGEN, Denmark, Feb. 3, 2026 /PRNewswire/ -- Announcement no. 5/2026 Interim Report Q4 and Full…

33 minutes ago

UAE Partners with Colossal Biosciences to Protect Biodiversity and Champion the Future of Life on Earth

The collaboration positions the UAE as a global leader in conservation, driving pioneering initiatives in…

33 minutes ago

Case Reports in Regrowth Announces Publication of Muhammad Qasim Observational Case Report and Invites Medical Review

New York, New York--(Newsfile Corp. - February 3, 2026) - Case Reports in Regrowth today…

1 hour ago